Hemostatic Agent Downclassification Should Await Guidance – Panel
This article was originally published in The Gray Sheet
Executive Summary
FDA plans to develop a draft guidance document for absorbable hemostatic agent 510(k) submissions and submit it for panel review before reconsidering downclassification of the devices
You may also be interested in...
Silicone Sheeting Becomes Class I Exempt Effective Sept. 8 – FDA Final Rule
Class I exempt status for silicone sheeting applies to use of the product on intact skin, FDA emphasizes in an 1Aug. 9 final rule
Silicone Sheeting Becomes Class I Exempt Effective Sept. 8 – FDA Final Rule
Class I exempt status for silicone sheeting applies to use of the product on intact skin, FDA emphasizes in an 1Aug. 9 final rule
Absorbable Hemostatic Agent Downclassification Endorsed By Panel
Content review of FDA's planned special controls guidance was instrumental in the General & Plastic Surgery Devices Panel's July 24 recommendation that absorbable hemostatic agents be downclassified from Class III to Class II
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Medtech Insight?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: